Lord's Mark Industries Limited has secured Medicines and Healthcare products Regulatory Agency (MHRA) registration for its In-Vitro Diagnostic (IVD) portfolio, enabling commercial sales in the United Kingdom from December 2026.

The registration, dated September 24, 2026, lists the company as a registered manufacturer. It covers specific IVD categories including haematological cell analysers, multiple clinical chemistry analysers, buffered sample diluents, and instrument cleaning agents. This milestone follows the recent MHRA registration for the company's AI-powered Renalyx haemodialysis system announced in September.

Accelerated commercial timeline

The company plans to commence commercial sales of its IVD products in the UK market from December 2026. This start date is approximately two months ahead of the earlier schedule. The accelerated timeline allows Lords Mark to leverage the UK as an international platform while pursuing opportunities across UK-allied markets, subject to local regulatory requirements.

Integrated healthcare strategy

Beyond product exports, the company is expanding into healthcare delivery services. A pathology laboratory is scheduled to commence operations in January 2027. This initiative aims to integrate diagnostic products with laboratory capabilities and healthcare delivery.

Dr. Sachidanand Upadhyay, MD & CEO, stated that the registrations demonstrate ambition beyond a single healthcare product. He noted the goal of building a broader diagnostics and healthcare platform with commercialisation planned ahead of schedule.

What the numbers show

The sequence of regulatory approvals highlights a rapid diversification of the company's international footprint within a single month. The MHRA registration for the Renalyx system occurred in September, followed immediately by the IVD portfolio registration on September 24, 2026. This tight clustering of approvals supports the decision to pull forward commercial sales by two months, indicating readiness for immediate market entry across both renal care technology and diagnostics segments.

Lords Mark Industries Limited promoter Sachidanand Hariram Upadhyay has proposed to reinvest the majority of proceeds from his recent share sale towards the strategic expansion of the company's medical device unit. The promoter sold 89,98,598 equity shares on September 29, 2026, generating net proceeds of ₹76,18,19,624.

This development follows the initial disclosure of the stake reduction under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The confirmation letter dated October 1, 2026, clarifies that the funds were credited to the promoter's bank account and outlines the intent to channel these resources back into the business through viable means.

Transaction details

The promoter group member executed the disposal exclusively through the open market mechanism on the BSE. No encumbrances such as pledges or liens were associated with the shares prior to or after the sale. The total diluted share capital remained unchanged as no convertible securities were involved.

Capital structure context

The company's total equity share capital consists of 42,66,22,217 equity shares of ₹10 each, aggregating to ₹426,62,22,170. This capital structure remains constant before and after the promoter's sale, as the transaction involved existing shares rather than new issuance. Following this sale, Upadhyay's holding stands at 31,14,40,648 shares, or 73.00% of the total voting capital. The disclosure was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015.

What the numbers show

The proposal to reinvest the majority of the ₹76.18 crore net proceeds signals a commitment to internal growth rather than personal liquidity extraction. While the promoter's stake decreased from 75.11% to 73.00%, maintaining a substantial majority above the 50% threshold for absolute control, the redirection of capital into the medical device unit suggests a strategic pivot or acceleration in that specific segment. The retention of 73% ownership ensures continued promoter influence over corporate decisions while leveraging external market liquidity for operational expansion.